Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cencora (COR)
NYSE:COR
Holding COR?
Track your performance easily
COR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$178.21 - $247.66
Previous Close$228.48
Volume2.20M
Average Volume (3M)1.45M
Market Cap
$45.02B
Enterprise Value$46.58B
Total Cash (Recent Filing)$3.31B
Total Debt (Recent Filing)$4.73B
Price to Earnings (P/E)25.5
Beta0.29
Next Earnings
Nov 07, 2024EPS Estimate
$3.21Last Dividend Ex-Date
Aug 09, 2024Dividend Yield0.87%
Share Statistics
EPS (TTM)9.21
Shares Outstanding197,046,826
10 Day Avg. Volume1,668,836
30 Day Avg. Volume1,447,649
Standard Deviation0.06
R-Squared0.16
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)48.61
Price to Sales (P/S)0.16
Price to Cash Flow (P/CF)4.70
P/FCF Ratio4.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.17
Enterprise Value/Gross Profit5.20
Enterprise Value/Ebitda12.72
Forecast
1Y Price Target
$267.10Price Target Upside17.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Cencora News
PremiumCompany Announcements
Cencora Announces EPS Forecast and Evernorth Contract Renewal
PremiumCompany Announcements
Cencora Enhances Governance and Executive Compensation Structures
PremiumCompany Announcements
Cencora Expands Board, Announces New Member AppointmentsBulls Say, Bears Say
Bulls Say
Acquisition And GrowthOneOncology's acquisition of the United Urology Group is a logical expansion, with potential for new customer wins for Cencora's Specialty Practice GPO.
Contract ExtensionLarge customer drug distribution contract extended. Evernorth Health Systems drug distribution contract extended for an additional three years through September 2029.
Financial PerformanceCencora raised FY 2024 adjusted EPS guidance by $0.05 to $13.60-$13.70 citing strong utilization and sales trends of specialty products to physicians and health systems and lower net interest expense.
Bears Say
Customer RelationshipsCigna recently extended its contract with Cencora, but is slowly shifting specialty distribution toward its internal subsidiary, CuraScript SD.
EarningsRelatively lower EPS growth rate creates a weaker forward return profile given the elevated earnings multiple.
Industry DynamicsIndustry growth is normalizing and the competitive dynamics are shifting.
---
Ownership Overview
12.83% Insiders
27.80% Mutual Funds
50.53% Other Institutional Investors
8.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
COR FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was $178.21 and its highest was $247.66 in the past 12 months.
What is Cencora’s market cap?
Currently, no data Available
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Jul 31, 2024. The company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.217 by $0.123.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of $0.51 which represents an annual dividend yield of 0.87%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is $3.21.
How many shares outstanding does Cencora have?
Cencora has 197,046,830 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $3.34 in its last earnings report, beating expectations of $3.217. Following the earnings report the stock price went up 2.967%.
Which hedge fund is a major shareholder of Cencora?
Among the largest hedge funds holding Cencora’s share is Antipodes Partners Ltd. It holds Cencora’s shares valued at 110M.
---
Cencora Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$267.10 (17.89% Upside)
$267.10 (17.89% Upside)
Blogger Sentiment
Bullish
COR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 169.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1B over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.79%
12-Months-Change
Fundamentals
Return on Equity
230.42%
Trailing 12-Months
Asset Growth
9.15%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. engages provision of pharmaceutical products and business solutions that improve access
to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical
Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic
pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded
sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and
health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate
site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and
includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.
---
COR Company Deck
---
COR Earnings Call
Q3 2024
0:00 / 0:00
---
COR Revenue Breakdown
87.62% Human Health
8.52% Alliance Healthcare
1.93% Other Healthcare Solutions
1.92% Animal Health
---
COR Stock 12 Month Forecast
Average Price Target
$267.10
▲(17.89% Upside)
Technical Analysis
Best Analysts Covering COR
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+19.65%
reiterated a buy rating 8 months ago
Copying Kevin Caliendo's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +19.65% per trade.
---